Literature DB >> 16014085

Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome.

Horatio A Repetto1.   

Abstract

In the classic form of hemolytic uremic syndrome associated with toxins of gram-negative enterobacteria, mortality in the acute stage has been lower than 5% since 1978 (data from the Nephrology Committee, Argentine Society of Pediatrics). Children usually die because of severe involvement of the central nervous system, intestine, or myocardium and its complications, or because of intercurrent infection. Treatment in this phase is supportive, and efforts should be put into prevention of infection by Shiga-like toxin-producing enterohemorrhagic Escherichia coli. Of the 95% who survive, approximately one third is at risk for having chronic sequelae. Motor, sensory, or intellectual deficits, intestinal strictures, myocardial infarctions, or diabetes are infrequent. The more-frequent chronic renal lesion is characterized by the hyperfunction of nephrons remaining after the acute necrotizing lesion, which leads to progressive scarring, and not by persistence or recurrence of the microangiopathic process. Three courses of progression to end-stage renal failure have been described. Children with most severe forms do not recover from acute renal failure and enter directly into a dialysis and transplantation program. A second group recovers renal function partially, with persistent proteinuria and frequently hypertension; progression to end-stage renal failure occurs in 2 to 5 years. The third group may recover normal serum creatinine and creatinine clearance, with persistent proteinuria. They are at risk of progressing to chronic renal failure and end-stage renal disease after more than 5 years, and sometimes as late as 20 years, after the acute disease. Treatment should aim at preventing the mechanisms associated with progressive renal scarring. Transplantation is indicated in this form of hemolytic uremic syndrome, because there is little, if any, risk of recurrence, and the prognosis is similar to that of transplantation for other diseases.

Entities:  

Mesh:

Year:  2005        PMID: 16014085     DOI: 10.1111/j.1523-1755.2005.09717.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  26 in total

1.  Seasonal variation of HUS occurrence and VTEC infection in children with acute diarrhoea from Argentina.

Authors:  M A Rivero; J A Passucci; E M Rodríguez; A E Parma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

2.  Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome.

Authors:  Carlos J Cobeñas; Paula S Bresso; Laura L Lombardi; Oscar R Amoreo; Javier D Ruscasso; Ana P Spizzirri; Ângela Del C Suarez; Javier H Zalba; Ricardo C Rahman; Paula Risso
Journal:  Pediatr Nephrol       Date:  2015-07-04       Impact factor: 3.714

3.  Methods for characterizing differences in longitudinal glomerular filtration rate changes between children with glomerular chronic kidney disease and those with nonglomerular chronic kidney disease.

Authors:  Christopher B Pierce; Christopher Cox; Jeffrey M Saland; Susan L Furth; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2011-08-09       Impact factor: 4.897

4.  Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.

Authors:  Maria Gracia Caletti; Mabel Missoni; Clarisa Vezzani; María Grignoli; Juan Jose Piantanida; Horacio A Repetto; Ramon Exeni; Stella Maris Rasse
Journal:  Pediatr Nephrol       Date:  2011-04-30       Impact factor: 3.714

5.  Incidence of Initial Renal Replacement Therapy Over the Course of Kidney Disease in Children.

Authors:  Derek K Ng; Matthew B Matheson; Bradley A Warady; Susan R Mendley; Susan L Furth; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

6.  Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli.

Authors:  Daniel A Vilte; Mariano Larzábal; Angel A Cataldi; Elsa C Mercado
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

7.  Designed coiled-coil peptides inhibit the type three secretion system of enteropathogenic Escherichia coli.

Authors:  Mariano Larzábal; Elsa C Mercado; Daniel A Vilte; Hector Salazar-González; Angel Cataldi; Fernando Navarro-Garcia
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

Review 8.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

9.  Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis.

Authors:  Carlos J Cobeñas; Laura F Alconcher; Ana P Spizzirri; Ricardo C Rahman
Journal:  Pediatr Nephrol       Date:  2007-06-13       Impact factor: 3.714

10.  Inhibition of water absorption and selective damage to human colonic mucosa are induced by subtilase cytotoxin produced by Escherichia coli O113:H21.

Authors:  Elizabeth Gerhardt; Mariana Masso; Adrienne W Paton; James C Paton; Elsa Zotta; Cristina Ibarra
Journal:  Infect Immun       Date:  2013-06-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.